A smartphone app, combined with wearable technology, will allow doctors to remotely monitor patients with conditions that limit their ability to voluntarily move their muscles. The app, known as 'aparito', uses a motion-tracking writsband to record the movements of patients with ataxia, and other related ambulatory conditions.
The prospect of widespread access to a life-changing drug for children with a rare muscular disorder is a step closer today after the United States Food and Drug Administration (FDA) granted accelerated approval for a new medication.
The Zayed Centre for Research into Rare Disease in Children (ZCR) is currently under construction in Guildford Street. Importantly this will include a dedicated facility comprising seven ‘cleanrooms’ where gene and cell therapy medicinal products can be made to treat children compassionately or on a clinical trial.
BRC-supported researcher Dr Kevin Mills has been awarded funding from the NIHR to investigate the regenerative ability of the liver following acute liver failure (ALF). If successful, the team hope that their research will lead to a novel therapy that could buy patients enough time to allow their livers to regenerate naturally, avoiding the need for liver transplants
A new protein that appears to play a role in mitochondrial disease – a rare condition where a lack of energy in cells means that they can’t function properly – could prove to be important in conditions such as Alzheimer’s, Parkinson’s and Huntington’s diseases.
This morning, the Chancellor of the Exchequer George Osborne visited Great Ormond Street Hospital (GOSH) to announce a new £800 million boost to biomedical research through the National Institute for Health Research (NIHR).
Sir Michael Rake, currently Chairman of the BT Group plc, has been appointed as the new Chairman of Great Ormond Street Hospital for Children NHS Foundation Trust and will take up the position in November 2017.
National Institute for Health Research (NIHR) Great Ormond Street Hospital (GOSH) BRC (Biomedical Research Centre) researchers, working in collaboration with the BRC at NIHR Queen Square Dementia and the Wolfson Biomarker Dementia consortium at Institute of Neurology (IoN), have developed a new test to diagnose different types of dementia, which they hope will allow for more reliable and accurate diagnosis of the neurodegenerative conditions of Lewy Body Dementia and Alzheimer’s disease.